Clinical trial · Observational
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
A Multidisciplinary Neuroscience Approach to Investigate Cognitive Impairment in Young Patients With Cancer Prospectively
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function. The aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemo-brain | — | UNRESOLVED | — |
| Chemotherapeutic Toxicity | — | UNRESOLVED | — |
| Chemotherapy-Related Cognitive Impairment | — | UNRESOLVED | — |
| Childhood Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Solid tumor patients
- description
- Patients diagnosed with solid tumor cancers
- label
- Haematological patients
- description
- Patients diagnosed with haematological cancers
Primary outcomes (3)
- measure
- Performance on clinical neurocognitive tests: Wechlers scale
- timeFrame
- T0: within 30 days of diagnosis
- description
- Scores on the clinical neurocognitive tests (Wechler Intelligence Scale for Children Fifth edition for participants 7-15.9 years of age, Wechler Adult Intelligence Scale Fourth edition for participants 16 years of age or older). Scaled scores range from 0-19, higher = better performance.
- measure
- Performance on clinical neurocognitive tests: Wechlers scale
- timeFrame
- T2: end of treatment (2 weeks after the final antineoplastic treatment)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 7 Years
- Maximum age
- 29 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet. * At the age of 7-29 years at diagnosis * Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin). Exclusion Criteria: * Unable to speak and understand Danish * Severe intellectual disability or mental health disorder that hinders participation * Brain metastases, * Terminal illness * Have had a previous chemotherapy or radiotherapy treatment
References
Publications (1)
- DERIVEDNordhjem BJT, Tjornlund M, Thomsen BL, Hjerming M, Kjaer TW, Pappot H, Hjalgrim LL. Protocol for a prospective, longitudinal study of cognitive impairment in young patients with cancer: a multidisciplinary neuroscience approach (MyBrain). BMJ Open. 2023 May 18;13(5):e070534. doi: 10.1136/bmjopen-2022-070534. PMID 37202143